Image

Global Women's Health Market – Industry Trends and Forecast to 2029

  • Healthcare
  • Upcoming Report
  • Jul 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60
  • Healthcare
  • Upcoming Report
  • Jul 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Women's Health Market, By Drugs (Prolia, XGEVA, EVISTA, Mirena, Zometa, Reclast or Aclasta, Minastrin 24 Fe, FORTEO, NuvaRing, Primarin, ACTONEL, ORTHO TRI-CY LO (28)), Application (Hormonal Infertility, Female Infertility, Postmenopausal Osteoporosis, Endometriosis, Contraception, Polycystic Ovary Syndrome (PCOS), Menopause, Other Applications) – Industry Trends and Forecast to 2029

Women's Health Market

Market Analysis and Size

The term "women's health" refers to procedures, medications, and surgical aids used to treat the different disorders affecting this population. These illnesses cover urology, nutrition, oncology, reproduction, menopause, and other medical specialties. The goal of women's health is to enhance overall health in women and better manage disease. Many governments are stepping up their efforts to raise awareness of women's health. To promote the health of women, some organisations, including the World Health Organization (WHO) and the US Food and Drug Administration (FDA), are launching new safety programmes.

Data Bridge Market Research analyses that the women’s health market which was USD 34.45 billion in 2021, would rocket up to USD 52.27 billion by 2029, and is expected to undergo a CAGR of 5.35% during the forecast period 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Report Scope and Market Segmentation

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2014 - 2019)

Quantitative Units

Revenue in USD Billion, Volumes in Units, Pricing in USD

Segments Covered

Drugs (Prolia, XGEVA, EVISTA, Mirena, Zometa, Reclast or Aclasta, Minastrin 24 Fe, FORTEO, NuvaRing, Primarin, ACTONEL, ORTHO TRI-CY LO (28)), Application (Hormonal Infertility, Female Infertility, Postmenopausal Osteoporosis, Endometriosis, Contraception, Polycystic Ovary Syndrome (PCOS), Menopause, Other Applications)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

Siemens (Germany), Hologic, Inc. (U.S.), Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (China), Abbott (U.S.), BD (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Thermo Fisher Scientific Inc. (U.S.), Koninklijke Philips N.V. (Netherlands), NeuroLogica Corp.(U.S.), Shimadzu Medical (India) pvt. Ltd. (Japan), GENERAL ELECTRIC (U.S.), Quest Diagnostics Incorporated (U.S.), Sysmex India Pvt. Ltd. (Japan), Hitachi, Ltd. (Japan), Canon Inc. (Japan), FUJIFILM Holdings Corporation (U.K.)

Market Opportunities

  • Rising rates of stress-related osteoarthritis
  • Fertilitry and other illnesses are expected to fuel the expansion of the women's health

Market Definition

Women's health includes treatments, medications, surgical procedures, and preventative measures for the female population's various ailments. These conditions may be distinct from those treated in urology, nutrition, cancer, reproductive, menopause, and other medical specialties. Women's health is focused on providing for improved disease management and boosting the general health of the female population.

Women's Health Market Dynamics

Drivers

  • Increase in chronic diseases

The rising frequency of chronic illnesses among women and the rise in demand for contraceptives to prevent unintended pregnancies are the main factors anticipated to fuel the growth of the women's health market during the forecast period. Additionally, the government's measures to slow population expansion and the increased focus on product research and development.

  • Development of new medicines

The growth in the number of women over 60 who adopt unhealthy lifestyle habits and the development of new medicines specifically for women are the main drivers of the global women's health market. Numerous illnesses affect women, including osteoporosis, osteoarthritis, anaemia, abnormalities of menstrual health, depression, and obesity. Therefore, the market expansion in the upcoming years is projected to be boosted by these rising illnesses.

  • Rising stress-related diseases

In addition, rising rates of stress-related osteoarthritis, infertility, and other illnesses are expected to fuel the expansion of the women's health industry in the area during the ensuing years, along with a number of government initiatives to raise health awareness.

Opportunities

Additionally, the development of the markets will soon present profitable chances for the expansion of the women's health market.

Restraints/Challenges

On the other side, it is predicted that the refusal to use contraceptives would hinder the expansion of the women's health market in the years to come.

This women’s health market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the women’s health market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Women's Health Market

Due to capital market and global economy uncertainty, limited transit options and travel restrictions created impediments to international trade and transportation during the COVID-19 pandemic, affecting the supply chain for women's health diagnostics and temporarily lowering demand. Unfavourable changes in rules and laws impede the advancement of this industry. According to major regulatory organisations, COVID-19 infection is more common in breast cancer patients than in healthy people. Screening, surgical operations, and diagnostic screenings at hospitals and breast cancer clinics have all been postponed or severely curtailed as a result.

Global Women's Health Market Scope

The women’s health market is segmented on the basis of drugs and application. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drugs

  • Prolia
  • XGEVA
  • EVISTA
  • Mirena
  • Zometa
  • Reclast
  • Aclasta
  • Minastrin 24 Fe
  • FORTEO
  • NuvaRing
  • Primarin
  • ACTONEL
  • ORTHO TRI-CY LO (28)

 Application

  • Hormonal Infertility
  • Female Infertility
  • Postmenopausal Osteoporosis
  • Endometriosis
  • Contraception
  • Polycystic Ovary Syndrome (PCOS)
  • Menopause
  • Other Applications

Women's Health Market Regional Analysis/Insights

The women’s health market is analysed and market size insights and trends are provided by country, drugs and application as referenced above.

The countries covered in the women’s health market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the women's health market due to the presence of key players and repayment policies.

Asia-Pacific is projected to observe significant amount of growth in the women's health market due to the upsurge in the consciousness about women’s wellbeing and health.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Competitive Landscape and Women's Health Market Share Analysis

The women’s health market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to women’s health market.

Some of the major players operating in the women’s health market are:

  • Siemens (Germany)
  • Hologic, Inc. (U.S.)
  • Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (China)
  • Abbott (U.S.)
  • BD (U.S.)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Thermo Fisher Scientific Inc. (U.S.)
  • Koninklijke Philips N.V. (Netherlands)
  • NeuroLogica Corp.(U.S.)
  • Shimadzu Medical (India) pvt. Ltd. (Japan)
  • GENERAL ELECTRIC (U.S.)
  • Quest Diagnostics Incorporated (U.S.)
  • Sysmex India Pvt. Ltd. (Japan)
  • Hitachi, Ltd. (Japan)
  • Canon Inc. (Japan)
  • FUJIFILM Holdings Corporation (U.K.)


SKU-

Why Choose Us


Frequently Asked Questions

Global Women's Health Care Market segmented By Application such as Hormonal Infertility, Female Infertility, Postmenopausal Osteoporosis, Endometriosis, Contraception, Polycystic Ovary Syndrome (PCOS), Menopause, Other Applications.
The major players covered in the women's health market report are Lilly, Novartis AG, Pfizer Inc., Merck & Co., Inc., Novo Nordisk A/S, Amgen Inc., Lupin Pharmaceuticals, Inc., AstraZeneca, F. Hoffmann-La Roche Ltd, Sanofi, Johnson & Johnson Services, Inc., GlaxoSmithKline plc, Bayer AG, TheramexAgile TherapeuticsBlairex Laboratories, Inc., Bristol-Myers Squibb Company, Ferring B.V., Abbott, Enteris BioPharmaEvestra, Inc.Gedeon Richter Plc., HRA Pharma, JDS Therapeutics, LLC, Neurocrine Biosciences, Inc.Noven Pharmaceuticals, Inc.Radius Health, Inc., TherapeuticsMD, Inc., Bausch & Lomb Incorporated, Vertical Pharmaceuticals, LLC, Veru Inc.BD, AbbVie Inc., among other domestic and global players
The Women's Health Market is to grow at a CAGR of 5.35% during the forecast by 2029.
The Women's Health Market value is expected USD 52.27 billion by 2029.